Inhibition of MAPK/ERK, PKC and CaMKII signaling blocks cytolysin-induced human glioma cell death

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1209-1215

  Soletti, Rossana C ^a,b   Alves, Tercia ^a   Vernal, Javier ^b   Terenzi, Hernán ^b   Anderluh, Gregor ^c   Borges, Helena L ^a   Gabilan, Nelson H ^b   Moura Neto, Vivaldo ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cytolysins; Equinatoxin II; Necrosis; Signaling pathways; Toxin Bc2

Indexed keywords

CALCIUM CALMODULIN DEPENDENT KINASE 2; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; EQUINATOXIN; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SEA ANEMONE TOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL SWELLING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NICK END LABELING; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL DEATH; CELL LINE, TUMOR; CNIDARIAN VENOMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GLIOBLASTOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MARINE TOXINS; MITOGEN-ACTIVATED PROTEIN KINASES; PERFORIN; PROTEIN KINASE C; STAUROSPORINE; THYMIDINE;

EID: 77953792337     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parker MW and Feil SC: Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol 88: 91-142, 2005.
2. Anderluh G and Macek P: Cytolytic peptide and protein toxins from sea anemones (Anthozoa: Actiniaria). Toxicon 40: 111-24, 2002.
3. Kreitman RJ: Recombinant immunotoxins containing truncanted bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23: 1-13, 2009.
4. Iacovache I, van der Goot FG and Pernot L: Pore formation: an ancient yet complex form of attack. Biochim Biophys Acta 8: 1611-1623, 2008.
5. Kristan KC, Viero G, Dalla Serra M, Maček P and Anderluh G: Molecular mechanism of pore formation by actinoporins. Toxicon, in press, 2009.
6. Malovrh P, Vieiro G, Serra MD, Podlezek Z, Lakey JH, Macek P, Menestrina G and Anderluh G: A novel mechanism of pore formation: membrane penetration by the N-terminal amphipathic region of equinatoxin. J Biol Chem 278: 22678-22685, 2003.
7. Migues PV, Leal RB, Mantovani M, Nicolau M and Gabilan NH: Synaptosomal glutamate release induced by the fraction Bc2 from the venom of the sea anemone Bunodosoma caissarum. Neuroreport 10: 67-70, 1999.
8. Soletti RC, de Faria GP, Vernal J, Terenzi H, Anderluh G, Borges HL, Moura-Neto V and Gabilan NH: Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells. Anticancer Drugs 19: 517-25, 2008.
9. Potrich C, Tomazzolli R, Dalla Serra M, Anderluh G, Malovrh P, Macek P, Menestrina G and Tejuca M: Cytotoxic activity of a tumour protease-activated pore-forming toxin. Bioconjug Chem 16: 369-376, 2005.
10. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO classification of tumours of the nervous system. J Neuropathol Exp Neurol 61: 215-225, 2000.
11. Louis DN, Ohgaki O, Wiestler OD and Cavenee WK (eds.): WHO Classification of Tumours of the Central Nervous System. Lyon: IARC Press, 4th ed., pp. 10-11, 2007.
12. Chiocca, EA, Broaddus WC, Gillies GT, Visted T and Lamfers LM: Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neurooncol 69: 101-117, 2004.
13. Rich JN and Bigner DD: Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 5: 430-446, 2004.
14. Panchal RG: Novel therapeutic strategies to selectively kill cancer cells. Biochem Pharmacol 55: 247-252, 1998.
15. Basso U, Ermani M, Vastola F and Brandes AA: Non-cytotoxic therapies for malignant gliomas. J Neurooncol 58: 57-69, 2002.
16. Parker MW and Feil SC: Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol 88: 91-142, 2005.
17. Zorec R, Tester M, Macek P and Mason WT: Cytotoxicity of equinatoxin II from the sea anemone Actinia equina involves ion channel formation and increase in intracellular calcium activity. J Membr Biol 118: 243-249, 1990.
18. + contribute to the swelling of differentiated neuroblastoma cells induced by equinatoxin-II. Toxicon 38: 1547-1560, 2000.
19. Berridge MJ, Lipp P and Bootman MD: The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1: 11-21, 2000.
20. Anderluh G, Pungercar J, Strukelj B, Macek P and Gubensek F: Cloning, sequencing, and expression of equinatoxin II. Biochem Biophys Acta 220: 437-442, 1996.
21. Faria J, Romão L, Martins S, Alves T, Mendes FA, de Faria GP, Hollanda R, Takiya C, Chimelli L, Morandi V, de Souza JM, Abreu JG and Moura Neto V: Interactive properties of human glioblastoma cells with brain neurons in culture and neuronal modulation of glial laminin organization. Differentiation 74: 562-572, 2006.
22. Gardner RS: A sensitive colorimetric assay for mitochondrial alpha-glycerophosphate dehydrogenase. Anal Biochem 59: 272-276, 1974.
23. Abdel-Latif L, Murray BK, Renberg RL, O'Neill KL, Porter H, Jensen JB and Johnson FB: Cell death in bovine parvovirus-infected embryonic bovine tracheal cells is mediated by necrosis rather than apoptosis. J Gen Virol 87: 2539-2548, 2006.
24. Adrian TE: Novel marine-derived anticancer agents. Curr Pharm Des 13: 3417-3426, 2007.
25. Mayer AM and Gustafson KR: Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds. Eur J Cancer 44: 2357-2387, 2008.
26. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
27. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and De Maria R: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13: 1238-1241, 2006.
28. Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C, von Deimling A and Siegelin MD: Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol 117: 445-456, 2009.
29. 2+ in chromaffin cells. J Biol Chem 275: 37488-37495, 2000.
30. Essman F, Bantel H, Totzke G, Engels IH, Sinha B, Schulze-Osthoff K and Janicke RU: Staphylococcus aureus alpha-toxin-induced cell death: predominant necrosis despite apoptotic caspase activation. Cell Death Differ 10: 1260-1272, 2003.
31. Kennedy CL, Smith DJ, Lyras D, Chakravorty A and Rood JI: Programmed cellular necrosis mediated by the pore-forming alpha-toxin from Clostridium septicum. PLoS Pathog 5: e1000516, 2009.
32. Koivunen J, Aaltonen V and Peltonen J: Protein kinase C (PKC) family in cancer progression. Cancer Lett 8: 1-10, 2005.
33. Vichi P, Whelchel A, Knot H, Nelson M, Kolch W and Posada J: Endothelin-stimulated ERK activation in airway smooth-muscle cells requires calcium influx and Raf activation. Am J Respir Cell Mol Biol 20: 99-105, 1999. (Pubitemid 129504847)
34. 2+ and calmodulin. Cell Signal 14: 649-654, 2002.
35. Festjens H, Vanden Berghe T and Vandenabeele P: Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 1757: 1371-1387, 2006.
36. Chang L and Karin M: Mammalian MAP kinase signaling cascades. Nature 410: 37-40, 2001.
37. Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007.
38. Chu CT, Levinthal DJ, Kulich SM, Chalovich EM and DeFranco DB: Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem 271: 2060-2066, 2004.
39. Ollinger R, Kogler P, Troppmair J, Hermann M, Wurm M, Drasche A, Konigsrainer I, Amberger A, Weiss H, Ofner D, Bach FH and Margreiter R: Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle 6: 3078-3085, 2007.
40. Stringaris AK, Geisenhainer J, Bergmann F, Balshusemann C, Lee U, Zysk G, Mitchell TJ, Keller BU, Kuhnt U, Gerber J, Spreer A, Bahr M, Michel U and Nau R: Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis 11: 355-368, 2002.